Division of Molecular Pathology | James Molecular Laboratory
Hematologic Neoplasms:
International reference laboratory for monitoring and resistance testing for BTK inhibitors
Identifying novel mechanisms of resistance to BTK inhibitors
Models of progression myeloid neoplasms
Improved genomic diagnosis of B-cell lymphoma
Developing algorithms to risk stratify patients with germline variants that may predispose to hematologic disorders
COVID-19 / SARS-CoV-2(Dan Jones, Matt Avenarius):
Novel diagnostics to simultaneously assess the viral microbiome, SARS-CoV-2 variants and host immune transcriptome in nasal mucosa (supported by NIH U54 and Ohio Frontier Fund)
Deep viral sequencing and viral microbiome profiles in environmental samples (with Jiyoung Lee, OSU School of Public Health, supported by Institute for Infectious Disease grant)
Assays to define key cardiovascular risk genomic predictors and biomarkers of myocarditis in patients with COVID-19 (with Richard Gumina, Division of Cardiovascular Medicine)
JML Bioinformatics Group:
Reporting tools for serial genomic monitoring of hematologic malignancies with NGS
Defining critical shifts in the viral microbiome for community surveillance activities
Reducing complexity in transcriptome RNAseq to limited signatures for routine diagnostic AI Deep Learning
Improved tools for MSI and fusion transcript detection from DNA-based NGS
Molecular Technology Development:
Developing a clinical trials companion diagnostic assay for T-DXd using quantitative digital imaging analysis for HER2 protein expression levels (Yan Hu)
Rapid DNA sequencing algorithms to speed therapy initiation in advanced and high-risk cancers
Improvement to digital droplet (dd) PCR methods for accurate rare event detection
Computer-assisted Fluorescence Imaging for FISH
Genomics of Neuromuscular Disorders (Matt Avenarius):
SMA advanced sequencing assays (supported by a Muscular Dystrophy Association Idea Grant)
